FDA Recalls for Foreign Manufacturers: Voluntary vs FDA-Requested

When to use this playbook

A food, drug, or medical device that your foreign facility manufactured is already in U.S. distribution, and a safety, quality, labeling, or compliance problem has emerged.
Your U.S. Agent, importer, or distributor has received an FDA recall inquiry, recommendation, formal request, or order.
Your company has decided to recall voluntarily but needs to coordinate FDA, U.S. inventory, distributors, direct accounts, and public communications from outside the country.
You need to determine which party owns each task instead of assuming the U.S. Agent conducts the recall.

This playbook assumes the foreign manufacturer is the product owner and recalling firm. If an FDA order or recall notice names a U.S. importer, distributor, or another responsible party, that named party becomes the primary owner for the duties assigned to it.

What success looks like

Affected lots stop moving before more U.S. customers receive them.
The manufacturer, U.S. Agent, importer, distributor, and FDA recall coordinator work from one product scope and one controlled communication record.
Every direct account receives clear instructions, downstream distribution is traced, and returned, corrected, or destroyed product is accounted for.
FDA receives the status information needed to classify, monitor, and eventually terminate the recall.

First determine which recall path you are on

Recall paths are defined by 21 CFR 7.45 and the FDA voluntary recall guidance.
Recall path	Who starts it	Legal character	What changes operationally
Firm-initiated voluntary recall	The manufacturer or another responsible firm decides to recall after identifying a distributed product problem.	The firm acts voluntarily and should notify FDA immediately.	The recalling firm develops the proposed strategy, starts direct-account notification, and does not wait for FDA classification before protecting customers.
FDA-recommended or FDA-requested recall	FDA identifies a concern and recommends or formally requests that the firm recall.	If the firm agrees, the recall is still considered voluntary. A formal request under 21 CFR 7.45 specifies the violation, health hazard classification, recall strategy, and appropriate instructions.	FDA takes a more directive role in the strategy, but the recalling firm still executes customer notification, product recovery, effectiveness checks, and reporting.
FDA-mandated or ordered recall	FDA issues an order under a product-specific statutory authority.	The named party must comply with the order, timetable, notification requirements, and reporting schedule.	Regulatory counsel should review the order immediately. The manufacturer and U.S. supply-chain parties still perform the operational work required to remove or correct the product.

The distinction buyers most often miss is that an FDA-requested recall is not automatically a mandatory recall. A firm that agrees to FDA's request is still conducting a voluntary recall. An order is different because it rests on a specific statutory authority and can impose legally enforceable actions and deadlines.

Where FDA can mandate a recall

Authorities: mandatory food recalls, mandatory device recalls, human drug recall authority, and controlled-substance recall authority.
Product category	FDA authority as of October 2, 2026	Key process distinction
Food other than infant formula	FDA can order a recall when the statutory risk threshold is met.	FDA must first give the responsible party an opportunity to stop distribution and recall voluntarily. If it does not, FDA can order a distribution stop, provide an informal hearing no later than two days after the order, and then require recall.
Medical devices	FDA can order a recall where there is a reasonable probability of serious adverse health consequences or death.	The process starts with a cease-distribution and notification order. The named party receives an opportunity for an informal hearing no later than 10 days after issuance before the order is amended to require recall.
Most human drugs	FDA can recommend or request a voluntary recall but does not have general mandatory recall authority.	Refusal can lead FDA to consider other enforcement actions, including seizure or injunction.
Controlled substances	FDA has specific authority to order nondistribution and recall when the statutory serious-risk threshold is met.	The process includes an opportunity to consult, a nondistribution order, and an opportunity for a hearing before the order is continued, vacated, or amended to require recall.

The U.S. Agent can start the foreign manufacturer's response clock

For foreign food facilities, FDA treats information or documents delivered to the U.S. Agent as equivalent to delivery to the foreign facility. Device and drug rules use the same basic communication principle when FDA cannot reach the foreign establishment directly or expeditiously. A foreign management team should therefore treat the agent's timestamp as the operational start of the response, not wait for the notice to circulate through overseas headquarters. FDA food facility guidance, FDA device U.S. Agent guidance, and FDA drug U.S. Agent guidance define these communication duties.

The practical implication is simple: a passive forwarding service can consume the first critical hours without technically conducting any part of the recall. A responsive U.S. Agent timestamps the notice, escalates it to named decision-makers, confirms receipt, and opens a shared record connecting the manufacturer, importer, distributor, and FDA contact.

Recall classification applies to every path

FDA assigns the recall classification based on the relative health hazard. The class does not tell you whether the recall was voluntary, requested, or ordered, and a manufacturer should not wait for classification before taking necessary protective action.

Classification definitions: 21 CFR 7.3.
Recall class	FDA meaning	Operational implication
Class I	There is a reasonable probability that use of or exposure to the product will cause serious adverse health consequences or death.	Expect the highest urgency, broader notification, intensive effectiveness checks, and a likely public warning.
Class II	Use or exposure may cause temporary or medically reversible adverse health consequences, or the probability of serious consequences is remote.	The recall still requires disciplined notification and product accounting, but its depth and public communication depend on the actual risk and distribution.
Class III	Use or exposure is not likely to cause adverse health consequences.	The action may focus on wholesale or retail correction and removal, with less extensive effectiveness checking.

A Class I medical device recall is not the same concept as a Class I medical device regulatory classification. One describes the hazard of a specific recall; the other describes the regulatory controls applicable to a type of device.

Foreign manufacturer recall responsibility map

This map assumes the parties are separate. In practice, the importer of record may also be the distributor, warehouse operator, device initial importer, or U.S. Agent. Assign work by actual function rather than company title.

This responsibility map synthesizes FDA product recall guidance with the limited communication role assigned to a U.S. Agent.
Recall stage	Foreign manufacturer	U.S. Agent	Importer of record	U.S. distributor	FDA recall coordinator
Notice intake	Appoints a decision-maker and confirms receipt.	Relays and escalates the notice, confirms receipt, and opens the communication log.	Provides entry, shipment, port, and warehouse information.	Confirms inventory locations and downstream movement.	Identifies the FDA concern and requests supporting information.
Stop distribution	Directs the global and U.S. shipment hold.	Confirms that instructions reached all U.S. parties.	Stops release of affected entries or warehouse inventory under its control.	Quarantines stock and blocks further orders.	May provide or order specific cease-distribution instructions.
Recall decision	Initiates voluntarily, agrees to an FDA request, or complies with an order.	Coordinates communication but does not make the recall decision merely because it holds the agent designation.	Acts as decision owner only if it is the recalling firm or a named party in an order.	Supports the decision with inventory and customer data.	Assesses whether the action is a recall and applies the appropriate FDA process.
Scope and strategy	Owns the technical investigation, affected products and lots, risk analysis, and proposed corrective action.	Organizes the submission, maintains version control, and routes FDA questions.	Supplies customs entry and shipment-level traceability.	Supplies direct-account, inventory, return, and sell-through data.	Reviews or develops the strategy, conducts the health hazard evaluation, and assigns the classification.
Customer notification	Approves the recall communication and instructions.	Coordinates FDA review and U.S. distribution of approved communications.	Notifies accounts it supplied directly when instructed.	Notifies its direct accounts and requires downstream extension where applicable.	Reviews communications and determines whether additional public notification is needed.
Recovery or correction	Sets return, correction, destruction, refund, or replacement instructions and funds the program.	Coordinates records and escalates execution gaps.	Controls affected entries and inventory in its possession.	Collects, segregates, corrects, returns, or destroys affected product.	Monitors whether disposition matches the strategy.
Effectiveness and reporting	Owns the complete product accounting and status reports.	Compiles U.S. updates, follows up on missing inputs, and transmits agreed submissions.	Reports shipment and inventory disposition.	Reports notifications, responses, returns, corrections, and nonresponding accounts.	Reviews status reports and may conduct recall audit checks.
Termination	Submits or approves the final status package and termination request.	Routes the request and relays FDA's written decision.	Confirms that controlled inventory has reached final disposition.	Closes outstanding customer and product records.	Determines whether reasonable efforts and proper disposition support termination.

Step 1: Stop movement and preserve the evidence

Action: Freeze shipment, sales, transfer, and release of potentially affected product. Quarantine U.S. stock and preserve samples, batch records, complaints, laboratory results, labels, shipment records, and correspondence. Identify the product name, lot or batch codes, expiration dates, UDI or NDC where applicable, quantities, and every known U.S. location.

Expected outcome: No additional affected product enters commerce, and the recall team can distinguish affected from unaffected inventory.

Gotchas: Do not destroy or rework product before the disposition plan and evidence requirements are settled. Do not define the recall by the first complaint alone if adjacent lots share raw materials, equipment, labels, or manufacturing conditions.

Operational target: Start immediately, ideally within the first few hours after credible notice of a distributed product problem.

Step 2: Establish the FDA channel and confirm the recall path

Action: Identify whether the event is firm-initiated, FDA-requested, or ordered. Contact the correct FDA recall coordinator and assign one U.S.-based person to control outbound and inbound communications. Foreign drug and device firms generally report a new recall to the coordinator covering the state where their U.S. Agent is located; FDA provides a headquarters contact for broader foreign-firm recall questions. FDA OII recall coordinators lists the current contacts.

Expected outcome: The manufacturer has a named FDA contact, a documented path, and a controlled list of requested information.

Gotchas: An FDA-requested recall may begin with an oral communication before written confirmation. Do not dismiss a phone call as informal, and do not wait for a letter before stopping distribution where the known risk already supports action.

Operational target: Same day.

Step 3: Define the scope and build the recall strategy

Action: Assemble the product identity, affected codes, reason for recall, discovery timeline, health-risk information, total manufactured quantity, U.S. distribution, direct accounts, current inventory, and proposed disposition. The strategy must address recall depth, public warning, and effectiveness checks. For a firm-initiated recall, the recalling firm develops the strategy; for an FDA-requested recall, FDA develops it for the circumstances. 21 CFR 7.42 defines these elements.

Expected outcome: Every participant knows which products, lots, customers, and distribution levels are covered and what each consignee must do.

Gotchas: The strategy can expand if investigation identifies additional products or lots. A recalling firm need not delay initiation while FDA reviews its proposed strategy or communications.

Operational target: Produce the initial scope and direct-account list as soon as the product can be identified reliably. Refine it continuously as evidence develops.

Step 4: Notify direct accounts and decide on public warning

Action: Send conspicuous recall communications to every affected direct account. Identify the product precisely, explain the reason and hazard, state whether use or distribution must stop, give return or correction instructions, request confirmation, and tell recipients whether they must notify their own accounts. Telephone outreach should be documented and followed by written or electronic confirmation.

Expected outcome: U.S. customers can identify affected stock, stop further movement, protect users, and report quantities on hand.

Gotchas: Direct-account notification, a public warning, and FDA's Enforcement Report are different communications. A public warning is generally reserved for serious hazards where direct notification alone is inadequate. The first recall communication to direct accounts or the public is treated as the recall initiation date. FDA public warning guidance explains the review and notification framework.

Operational target: Promptly after the recall decision. High-risk cases require communication in hours rather than a staged marketing-style announcement process.

Step 5: Recover, correct, or control the product

Action: The importer, warehouse, and distributor execute the approved disposition instructions. Depending on the product and risk, this may involve segregation, return, on-site correction, relabeling, destruction, refund, replacement, or instructions to stop use. Maintain records that connect every action to a consignee, quantity, lot, date, and final disposition.

Expected outcome: The affected product is removed from use or corrected to the depth specified in the strategy.

Gotchas: The U.S. Agent does not physically retrieve product merely because it received the FDA communication. Separate regulatory reports may also apply, including device correction or removal reports, Field Alert Reports, Reportable Food Registry submissions, or adverse event reports. U.S. Agent designation alone does not transfer those reporting duties to the agent. FDA expressly excludes device adverse event reporting from the device U.S. Agent's designated responsibilities. FDA device U.S. Agent responsibilities.

Time estimate: Execution may run from days to weeks depending on distribution depth, but inventory controls and account outreach should begin immediately.

Step 6: Run effectiveness checks and status reporting

Action: Verify that consignees received the notice, understood it, stopped the required activity, and handled the product correctly. Track accounts notified, responses, nonresponders, quantities on hand, quantities returned or corrected, product accounted for, effectiveness-check results, and the estimated completion date.

Expected outcome: The manufacturer and FDA can determine whether the recall is actually reaching the intended distribution depth rather than merely counting sent emails.

Gotchas: Nonresponse is not evidence of completion. Escalate unanswered notices by telephone, alternative contacts, distributor channels, or documented site outreach. The recalling firm remains responsible for the data even when the U.S. Agent compiles and transmits it.

Time estimate: FDA sets the interval for each case. Voluntary recall status reports are generally submitted every 2 to 4 weeks under 21 CFR 7.53.

Step 7: Request and document FDA termination

Action: Submit the final product accounting, effectiveness results, consignee status, disposition records, and any corrective-action information FDA requests. The termination request should demonstrate that reasonable efforts were made and that the recalled product was removed or corrected consistently with the strategy and degree of hazard.

Expected outcome: FDA issues written notification terminating the recall.

Gotchas: Operational completion is not the same as FDA termination. Do not describe the recall as terminated merely because all known U.S. inventory has been returned. Status reporting continues until FDA terminates the recall. 21 CFR 7.55 defines the termination standard.

Time estimate: There is no universal termination period. Timing depends on risk, distribution depth, response rates, product accounting, and final disposition.

What FDA Entry Point does during a recall

FDA Entry Point receives and escalates recall communications, provides same-day crisis triage, connects the foreign manufacturer with the appropriate FDA contact, and coordinates the U.S. communication record among the manufacturer, importer, distributor, broker, and warehouse. Its broader service model also allows connected registration, listing, labeling, Prior Notice, SPL, or GUDID records to be reviewed when those records affect the product identity or response. FDA Entry Point U.S. Agent services and its urgent FDA response process define this coordination role.

FDA Entry Point is the best fit when

The foreign manufacturer has no U.S.-based regulatory operator available to control the FDA correspondence and recall workstream.
The existing U.S. Agent only forwards messages and cannot keep the manufacturer, importer, distributor, and FDA coordinator aligned.
The event also exposes registration, listing, labeling, product-code, or submission records that must be corrected through the appropriate FDA system.
Time-zone delays and unclear ownership are already consuming the response window.

What FDA Entry Point does not replace

The manufacturer's authority and obligation to initiate, fund, and execute its recall.
The importer or distributor's physical control of U.S. inventory and customer relationships.
Separate adverse event, Field Alert, correction or removal, or other product-specific reporting duties.
Legal representation in contested enforcement proceedings, administrative hearings, injunctions, seizures, or litigation. FDA regulatory counsel should lead those matters.

Frequently asked questions

What is the difference between a voluntary recall and an FDA-mandated recall?

A voluntary recall is initiated or accepted by the responsible firm, while a mandated recall is imposed through a product-specific FDA order. A recall remains voluntary when FDA recommends or formally requests it and the firm agrees. FDA can mandate qualifying food and medical device recalls and has specific authority for controlled substances, but most human drug recalls remain voluntary or FDA-requested. The operational recall still depends on the manufacturer and U.S. supply chain identifying customers, controlling inventory, recovering product, and reporting progress.

Who helps a foreign manufacturer manage an FDA-initiated recall?

The foreign manufacturer should appoint an internal recall lead, while its U.S. Agent manages the FDA communication channel and coordinates U.S. participants. The importer provides entry and shipment records, the distributor controls inventory and downstream customer notification, and the FDA recall coordinator reviews the strategy, assigns classification, and monitors effectiveness. Regulatory counsel should join immediately when FDA issues an order, a hearing is involved, or the company disputes the agency's authority or findings.

Does my U.S. Agent play a role if FDA requests a recall?

Yes, the U.S. Agent should relay the request immediately, confirm that responsible management received it, connect the manufacturer with the correct FDA coordinator, and maintain a controlled record of questions, submissions, and status updates. The agent can help organize the response and keep U.S. parties aligned, but the designation does not make the agent the recalling firm. The manufacturer or other responsible firm must agree to the request, define the affected product, authorize customer communications, and execute the recall.

Can a foreign manufacturer wait for FDA to classify the recall before notifying customers?

No, a manufacturer should not delay necessary protective action while waiting for FDA classification or strategy review. FDA treats the first communication to direct accounts or the public as the initiation date, and its guidance allows a voluntary recall to begin before FDA completes its review. The manufacturer should stop distribution, identify affected products, notify direct accounts promptly, and continue refining the scope with FDA as the investigation develops.

Does a U.S. Agent conduct effectiveness checks or file adverse event reports?

A U.S. Agent can coordinate effectiveness checks and compile the resulting data when separately engaged to do so, but the recalling firm ordinarily remains responsible for ensuring the checks are performed. U.S. Agent designation by itself also does not transfer adverse event reporting duties. FDA expressly limits the device U.S. Agent role to communication, questions about imported devices, and inspection scheduling, while excluding Medical Device Reporting responsibility from the designation.